A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Clinical trial NCT03251924 · TERMINATED
Trial details
- NCT number
- NCT03251924
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-01
- Primary completion
- 2021-12-20
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.